Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors.

Welker ME, Kulik G.

Bioorg Med Chem. 2013 Jul 15;21(14):4063-91. doi: 10.1016/j.bmc.2013.04.083. Epub 2013 May 9. Review.

2.

New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).

Feldman ME, Shokat KM.

Curr Top Microbiol Immunol. 2010;347:241-62. doi: 10.1007/82_2010_64. Review.

PMID:
20549474
3.

A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate.

Falasca M, Chiozzotto D, Godage HY, Mazzoletti M, Riley AM, Previdi S, Potter BV, Broggini M, Maffucci T.

Br J Cancer. 2010 Jan 5;102(1):104-14. doi: 10.1038/sj.bjc.6605408.

4.

Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.

Chiarini F, Falà F, Tazzari PL, Ricci F, Astolfi A, Pession A, Pagliaro P, McCubrey JA, Martelli AM.

Cancer Res. 2009 Apr 15;69(8):3520-8. doi: 10.1158/0008-5472.CAN-08-4884. Epub 2009 Apr 7.

5.

Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.

Dienstmann R, Rodon J, Serra V, Tabernero J.

Mol Cancer Ther. 2014 May;13(5):1021-31. doi: 10.1158/1535-7163.MCT-13-0639. Epub 2014 Apr 18. Review.

6.

Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.

Guenther MK, Graab U, Fulda S.

Cancer Lett. 2013 Sep 1;337(2):200-9. doi: 10.1016/j.canlet.2013.05.010. Epub 2013 May 16.

PMID:
23684925
7.

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

Wu P, Hu YZ.

Curr Med Chem. 2010;17(35):4326-41. Review.

PMID:
20939811
8.

Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series.

Cheng H, Hoffman JE, Le PT, Pairish M, Kania R, Farrell W, Bagrodia S, Yuan J, Sun S, Zhang E, Xiang C, Dalvie D, Rahavendran SV.

Bioorg Med Chem Lett. 2013 May 1;23(9):2787-92. doi: 10.1016/j.bmcl.2013.02.020. Epub 2013 Feb 13.

PMID:
23506825
9.

Targeting the PI3-kinase/Akt/mTOR signaling pathway.

Hassan B, Akcakanat A, Holder AM, Meric-Bernstam F.

Surg Oncol Clin N Am. 2013 Oct;22(4):641-64. doi: 10.1016/j.soc.2013.06.008. Epub 2013 Aug 6. Review.

10.

Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR.

Liu Q, Xu C, Kirubakaran S, Zhang X, Hur W, Liu Y, Kwiatkowski NP, Wang J, Westover KD, Gao P, Ercan D, Niepel M, Thoreen CC, Kang SA, Patricelli MP, Wang Y, Tupper T, Altabef A, Kawamura H, Held KD, Chou DM, Elledge SJ, Janne PA, Wong KK, Sabatini DM, Gray NS.

Cancer Res. 2013 Apr 15;73(8):2574-86. doi: 10.1158/0008-5472.CAN-12-1702. Epub 2013 Feb 22.

11.

[PI3K-AKT-mTOR pathway inhibitors].

Cortot A, Armand JP, Soria JC.

Bull Cancer. 2006 Jan;93(1):19-26. Review. French.

12.

PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.

Li H, Zeng J, Shen K.

Arch Gynecol Obstet. 2014 Dec;290(6):1067-78. doi: 10.1007/s00404-014-3377-3. Epub 2014 Aug 3. Review.

PMID:
25086744
13.

Developments in selective small molecule ATP-targeting the serine/threonine kinase Akt/PKB.

Wang P, Zhang L, Hao Q, Zhao G.

Mini Rev Med Chem. 2011 Nov;11(13):1093-107. Review.

PMID:
22353219
14.

The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis?

Malemud CJ.

Future Med Chem. 2015;7(9):1137-47. doi: 10.4155/fmc.15.55. Review.

PMID:
26132523
15.

Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors.

Ewald F, Nörz D, Grottke A, Hofmann BT, Nashan B, Jücker M.

Invest New Drugs. 2014 Dec;32(6):1144-54. doi: 10.1007/s10637-014-0149-7. Epub 2014 Aug 26.

PMID:
25152244
16.

Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.

Zhou Q, Lui VW, Yeo W.

Future Oncol. 2011 Oct;7(10):1149-67. doi: 10.2217/fon.11.95. Review. Erratum in: Future Oncol. 2012 Jan;8(1):112.

PMID:
21992728
17.

Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells.

Fiskus W, Verstovsek S, Manshouri T, Smith JE, Peth K, Abhyankar S, McGuirk J, Bhalla KN.

Mol Cancer Ther. 2013 May;12(5):577-88. doi: 10.1158/1535-7163.MCT-12-0862. Epub 2013 Feb 27.

18.

Targeting PI3K/AKT/mTOR network for treatment of leukemia.

Bertacchini J, Heidari N, Mediani L, Capitani S, Shahjahani M, Ahmadzadeh A, Saki N.

Cell Mol Life Sci. 2015 Jun;72(12):2337-47. doi: 10.1007/s00018-015-1867-5. Epub 2015 Feb 25. Review.

PMID:
25712020
19.

Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.

Li H, Jin X, Zhang Z, Xing Y, Kong X.

Cell Biochem Funct. 2013 Jul;31(5):427-33. doi: 10.1002/cbf.2917. Epub 2012 Oct 22.

PMID:
23086777
20.

Synthesis and evaluation of pyrrolotriazine based molecules as PI3 kinase inhibitors.

Dugar S, Hollinger FP, Kuila B, Arora R, Sen S, Mahajan D.

Bioorg Med Chem Lett. 2015 Aug 15;25(16):3142-6. doi: 10.1016/j.bmcl.2015.06.007. Epub 2015 Jun 10.

PMID:
26112437

Supplemental Content

Support Center